Inhibrx Biosciences INBX
NASDAQ INBX
$89.98 -0.63 (-0.70%)
As of: Nov 11, 2026 · 10:57 AM EST

Inhibrx Biosciences (INBX) Net Equity Issued and Repurchased (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) reported Net Equity Issued and Repurchased of $1.25 million for Q4 2025, up 256.3% from the prior quarter.

Analysis

Inhibrx Biosciences (INBX) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends

For FY2025, Inhibrx Biosciences posted Net Equity Issued and Repurchased of $1.61 million, down 97.8% from FY2024.

  • By year, Net Equity Issued and Repurchased came in at $71.68 million in FY2024 (-64.6%) and $202.32 million in FY2023.
  • The Q4 2025 figure ranks as the highest quarterly Net Equity Issued and Repurchased since Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -377.00 Mn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -966.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -5.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -406.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -283.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Inhibrx Biosciences 1.33 Bn 760.41 Mn - 1.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.60 Mn
Mar 31, 2026 471,000.00
Dec 31, 2025 1.25 Mn
Sep 30, 2025 352,000.00
Jun 30, 2024 32.95 Mn
Mar 31, 2024 38.73 Mn
Dec 31, 2023 1.09 Mn
Sep 30, 2023 200.02 Mn
API Access

Inhibrx Biosciences Net Equity Issued and Repurchased API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=INBX&period=max&api_key=YOUR_API_KEY